FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to coated pharmaceutical formulations with a controlled-release active substance and to the use thereof for treating benign prostatic hyperplasia. The formulation contains a therapeutically effective amount of the active substance representing tamsulosin or its pharmaceutically acceptable salt encapsulated in a granulated core, and an insoluble permeable polymer found both in the granulated core and in the coating. Said pharmaceutical formulations may also contain a surfactant and other optional excipients. Besides, the invention refers to a method for preparing the pharmaceutical formulations which involves mixing core ingredients, granulating, pressing and shaping in a sphere, drying and coating.
EFFECT: invention provides the formulations with pH-independent release of the active substance, low inter-individual variability and low biological variability.
14 cl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COATED COMPOUND CONTAINING PHARMACEUTICAL AGENT | 2004 |
|
RU2372893C2 |
| CHRONOTHERAPEUTIC PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2571067C2 |
| PHARMACEUTICAL DRUG CONTAINING BENZYMIDAZOL DERIVATIVE MIXED WITH MICROCRYSTAL CELLULOSE, AND METHOD OF ITS OBTAINING | 2003 |
|
RU2332237C2 |
| MODIFIED RELEASE 6-METHYL-2-ETHYL-HYDROXYPYRIDINE SUCCINATE DOSAGE FORM | 2008 |
|
RU2411035C2 |
| MEDICINAL RETARD-FORMULATION CONTAINING TRAMADOL SACCHARINATE | 2000 |
|
RU2292877C2 |
| TABLET WITH ENTEROSOLUBLE COATING AND METHOD OF PREPARING | 1998 |
|
RU2201217C2 |
| HYDROCODON PREPARATIVE SUSTAINED-RELEASE FORMULATIONS | 2000 |
|
RU2230556C2 |
| DOSAGE FORMS OF RISEDRONATE | 2005 |
|
RU2381791C2 |
| NEW CONTROLLED-RELEASE GRANULES AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH GRANULES | 1995 |
|
RU2141822C1 |
| PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
